NeuroBo Entered into a Conditional Exclusive License Agreement with Dong-A to Develop and Commercialize DA-1241 and DA-1726
Shots:
- Dong-A to receive $22M up front in Series A convertible preferred stock along with an additional fee upon achievement of specific regulatory & commercial milestones along with royalties on net sales of DA-1241 & DA-1726 (currently being evaluated for the NASH, obesity & T2D). The transaction is expected to close in Q3’22
- NeuroBo will lead the global development, regulatory & commercial activities other than for Asian-Pacific geographies. Dong-A will be responsible to manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Korea
- The P-Ia study of DA-1726 & P-IIa study of DA-1241 is expected to be initiated in H2’23 & H1’23 & the results are expected in H2’23 & H2’24
Ref: PRNewswire| Image: NeuroBo
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
